You are currently viewing a new version of our website. To view the old version click .

Biomedicines

Biomedicines is an international, peer-reviewed, open access journal on biomedicines published monthly online by MDPI.

Indexed in PubMed | Quartile Ranking JCR - Q1 (Pharmacology and Pharmacy)

All Articles (15,741)

Background: Tumor-lysate vaccines can capture tumor heterogeneity; however, their effectiveness may be reduced by antigen instability and short antigen presentation. Here, we aimed to improve antigen protection and prolong presentation by using a slow-degrading polymeric nanocarrier and an approved adjuvant. Methods: We encapsulated breast cancer cell lysates (MCF-7 and MDA-MB-231) in poly(ε-caprolactone) (PCL) nanoparticles using a double-emulsion (w/o/w) method and co-administered them with alum. We then characterized particle size, PDI, zeta potential, morphology, and in vitro release. Next, we evaluated nitric oxide (NO), TNF-α/IL-10 responses, and cytocompatibility in J774 macrophages. Finally, we quantified serum antibody titers in Balb/c mice after six biweekly immunizations, generated hybridomas, purified IgG, and tested antibody-mediated cytotoxicity alone and together with doxorubicin. Results: PCL nanoparticles were ~220–255 nm (PDI 0.10–0.19; ζ −2 to −3 mV) and released ~90–95% of encapsulated lysate by 800 h (~33 days). Encapsulated lysate (40 μg/mL) modestly increased NO versus control and increased further with alum (p < 0.05). TNF-α increased 7.4–9.72-fold, whereas IL-10 rose 2.82–3.11-fold. Importantly, encapsulated antigen + alum produced the highest ELISA responses after the sixth dose (6.36-fold for MCF-7 and 7.00-fold for MDA-MB-231 versus control; p < 0.05). Hybridoma-derived antibody signals increased through day 42, and Protein G purification yielded up to ~395 μg and ~318 μg IgG. Purified antibodies reduced cell viability, and viability decreased further when antibodies were combined with doxorubicin (to ~31.6% in MCF-7 and ~40.3% in MDA-MB-231). Conclusions: Overall, sustained PCL-mediated antigen release combined with alum strengthened humoral responses to tumor lysate and enabled recovery of functional antibodies with diagnostic capture and in vitro cytotoxic activity. In future work, key mechanistic steps such as lymph-node trafficking and cross-presentation should be tested directly.

1 January 2026

Conceptual mechanism of the PCL nanoparticle tumor-lysate vaccine. PCL nanoparticles are taken up by endocytosis, enabling endosomal escape and providing protected, slow release of tumor antigens, resulting in sustained antigen presentation and the induction of humoral responses together with functional T-cell immunity.

Background/Objectives: Familial adenomatous polyposis (FAP) is an autosomal dominant disorder caused by pathogenic variants in the adenomatous polyposis coli (APC) gene. Its attenuated form (AFAP) is characterized by fewer colorectal polyps and later onset of colorectal cancer. We aimed to characterize the molecular effects of a novel APC gene variant (NM_000038.6: c.1620_1624delinsT) identified in a patient with AFAP. Methods: A 56-year-old man with the AFAP phenotype underwent germline testing via a multigene NGS panel, which identified a novel APC gene variant (NM_000038.6: c.1620_1624delinsT). In silico analyses predicted disruption of the canonical donor splice site and a frameshift followed by the introduction of a premature stop codon. The transcriptional impact of the identified APC gene variant was investigated by mRNA analysis. Results: mRNA analysis revealed two distinct APC transcripts: the first transcript led to a truncated protein (p.Leu540PhefsTer8), and the second transcript lacked exon 12, resulting in an in-frame 26 amino acid deletion of APC protein (p.Ala517_Gly542del). The transcript lacking exon 12 was more abundant than the transcript with a premature stop codon, likely due to degradation through nonsense-mediated decay. Conclusions: The APC gene variant (NM_000038.6: c.1620_1624delinsT) exhibits a dual transcriptional effect, revealing its pathogenic role in AFAP. This study highlights the diagnostic value of combined DNA–RNA germline testing for improving the clinical classification of novel APC gene variants and their genotype–phenotype correlations in FAP.

1 January 2026

Pedigree of the family included in this study. Squares indicate men and circles women. The arrow indicates the index case. Unfilled symbols indicate unaffected individuals. Slashed symbols denote dead individuals. Black-filled symbols represent individuals with cancer. Gray-filled symbols denote individuals with colorectal polyps (CPs), and unfilled symbols denote individuals without cancer. Roman numerals (I–III) denote the generation to which each individual belongs. Arabic numerals identify individuals according to their position in the pedigree, numbered consecutively from left to right starting at 1. The following clinical manifestations are noted below each filled symbol: (CRC = colorectal cancer; LC = lung cancer; OvCa = ovarian cancer; CP = colon polyp; CPs = colon polyps), age at diagnosis (y = years), and age of death (†). The presence and the absence of heterozygous pathogenic variants (PVs) are also shown (APC +/− = presence of heterozygous PV; MSH2 +/− = presence of heterozygous PV; APC −/− = absence of heterozygous PV).

Background/Objectives: Osteoarthritis (OA) is a multifactorial degenerative joint disease characterized by synovial inflammation, oxidative stress, and progressive cartilage degeneration. This study investigated whether intra-articular N-acetylcysteine (NAC) attenuates synovial inflammation and oxidative stress and whether these effects translate into structural cartilage protection. Methods: OA was induced in rats by anterior cruciate ligament transection (ACLT). NAC (5 mg/50 µL) was administered intra-articularly once weekly for three weeks post-ACLT. Inflammatory cytokines (IL-1β, IL-6, TNF-α), oxidative stress markers (iNOS, TAS, TOS, OSI), and cartilage degradation markers (MMP-13, COMP, CTX-II) were quantified in synovial fluid and cartilage homogenates using ELISA. Cartilage integrity was evaluated histologically using the modified Mankin scoring system. Results: Compared with controls, NAC significantly reduced synovial IL-1β, IL-6, TNF-α, MMP-13, and iNOS levels and improved the synovial redox profile by increasing TAS and reducing TOS and OSI (all p < 0.05). In contrast, NAC did not significantly alter cartilage homogenate levels of inflammatory cytokines, oxidative stress indices, or degradation markers (COMP, CTX-II, MMP-13). Histological analysis demonstrated persistent cartilage fissuring, hypocellularity, and proteoglycan loss in both groups (p > 0.05). Conclusions: Intra-articular NAC exerts potent anti-inflammatory and antioxidative effects within the synovial compartment but fails to prevent cartilage degeneration in the ACLT model. These findings indicate a compartment-specific therapeutic profile, suggesting that NAC may function as a symptom-modifying agent in synovitis-dominant OA rather than a structure-modifying therapy. Future studies should focus on optimized delivery systems or combination strategies targeting cartilage and subchondral bone to achieve disease modification.

31 December 2025

Representative histological sections of rat knee joints from ACLT-operated control and NAC-treated groups stained with hematoxylin–eosin (H&amp;E) and Safranin O/Fast Green. Panels (A,C,E,G,I,K) represent the control group, whereas panels (B,D,F,H,J,L) represent the NAC-treated group. At low magnification, panels (A,B) demonstrate tidemark irregularities (black arrows) and loss of articular cartilage (white arrows) in the ACLT-operated control group (A), and clefts extending to the radial zone (black arrow) in the NAC-treated group (B) (H&amp;E, 4× and 20×). At higher magnification, panels (C,D) show the cartilage–subchondral bone interface, with cartilage tissue (a), bone tissue (b), loss of articular cartilage (c), apoptotic chondrocytes (d), and chondrocytes (e) in the ACLT-operated control group (C), while the NAC-treated group (D) demonstrates an irregular articular surface, clefts extending to the transitional zone (black arrows), and hypocellularity (H&amp;E, 10× and 40×). Panels (E,F) demonstrate a cleft extending to the transitional zone (black arrow) accompanied by chondrocyte clustering (white arrow) in the ACLT-operated control group (E), and clefts extending to the radial zone (black arrow) with hypocellularity in the NAC-treated group (F) (H&amp;E, 40×). In panels (G,H) clefts extending to the radial zone (black arrow) with cloning of chondrocytes in the transitional and radial layers and marked hypercellularity are observed in the ACLT-operated control group (G), while decreased cartilage thickness and partial loss of cartilage (black arrow) are observed in the NAC-treated group (H) (H&amp;E, 20×). In advanced degeneration fields, panels (I,J) demonstrate a cleft extending to the radial zone (black arrow), tidemark irregularity, and loss of articular cartilage (*) in the ACLT-operated control group (I), and loss of cartilage (black arrow) with hypocellularity in the transitional and radial zones in the NAC-treated group (J) (H&amp;E, 40×). Finally, Safranin O/Fast Green staining in panels (K,L) demonstrates regions marked with an asterisk (*) showing reduced red staining, indicative of proteoglycan depletion, while black arrows denote areas of articular surface erosion in both groups (×20; scale bar = 100 µm). TM: tidemark; UC: uncalcified cartilage.

Exploring the Benefits of Cranberries in Dentistry: A Comprehensive Review

  • Isabella Schönhofen Manso,
  • Yasmim Guterres Bauer and
  • Eduarda Blasi Magini
  • + 3 authors

Objectives: Despite the increasing scientific evidence regarding the application of Cranberries in dentistry, a comprehensive understanding of their potential benefits, active constituents, and mechanisms of action remains lacking. Consequently, this narrative review aims to meticulously analyze and consolidate the existing scientific literature on the utilization of Cranberries for the prevention and treatment of oral diseases. Materials and Methods: Electronic databases (PubMed, Scopus, and Web of Science) were searched up to October 2025. This review included in vitro, in vivo, and clinical research studies. A two-phase selection process was carried out. In phase 1, two reviewers independently screened titles and abstracts to identify potentially eligible studies. In phase 2, the same reviewers performed the full-text assessments of the eligible articles. Results: Among the 93 eligible articles, most assessed Cranberry use in Cariology (n = 28) and Periodontics (n = 26). Biofilm and microbial virulence factors (n = 46) were the most frequently studied topics. Cranberry extract (n = 32) and high-molecular-weight non-dialyzable material (NDM) (n = 23) were the most evaluated Cranberry fractions. Overall, Cranberry-derived compounds were identified as non-toxic and demonstrated promising antimicrobial activity against dental caries-related microorganisms in preclinical studies (n = 20). Regarding periodontal and peri-implant diseases, Cranberry demonstrated host immune modulator effects, counteracting the inflammatory and destructive mechanisms (n = 8). Additionally, Cranberries presented benefits in reducing the inflammation associated with periodontal disease and temporal mandibular joint lesions (n = 1). Regarding dental erosion, Cranberry inhibited dentin erosion (n = 4); however, no effect was observed on enamel lesions (n = 2). As an antioxidant agent, Cranberry showed effectiveness in preventing dental erosion (n = 18). Beyond that, Cranberry neutralized reactive oxygen species generated immediately after dental bleaching, enhancing bond strength (n = 2) and counteracting the oxygen ions formed on the tooth surface following bleaching procedures (n = 3). In osteoclastogenesis assays, A-type proanthocyanidins inhibited bone resorption (n = 1). In osteogenic analysis, preservation of hydroxycarbonate apatite deposition and an increase in early and late osteogenic markers were observed (n = 2). Conclusions: Cranberry bioactive compounds, both individually and synergistically, exhibit substantial potential for diverse applications within dentistry, particularly in the prevention and management of oral and maxillofacial diseases. This review provides insights into the plausible incorporation of Cranberries in contemporary dentistry, offering readers an informed perspective on their potential role.

31 December 2025

Flowchart of the literature search. References were selected through a two-phase process. Electronic databases (PubMed, Scopus, and Web of Science) were searched up to October 2025.

News & Conferences

Issues

Open for Submission

Editor's Choice

Reprints of Collections

Vitamin D in Health and Disease
Reprint

Vitamin D in Health and Disease

Editors: Giuseppe Murdaca, Sebastiano Gangemi
Vitamin D in Health and Disease (2nd Edition)
Reprint

Vitamin D in Health and Disease (2nd Edition)

Editors: Giuseppe Murdaca, Sebastiano Gangemi

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Biomedicines - ISSN 2227-9059